What were the main drivers of Abbott's revenue growth in 2002?

Abbott's revenue growth in 2002 was primarily driven by its Pharmaceutical Products segment, which saw a 13.5% increase in sales, and its International segment, which grew by 14.0%. Key product performance, including strong sales for Depakote, Biaxin, and the launch of Humira™, contributed significantly to this growth.

What is the status of the FDA consent decree concerning Abbott's diagnostics manufacturing operations?

Abbott incurred a $129 million pretax charge in 2002 related to the FDA consent decree. The company's diagnostics manufacturing operations in Lake County, Illinois, were found not to be in conformity with the FDA's Quality System Regulation in May 2002. Abbott is continuing its efforts to achieve full compliance, and further costs and potential revenue loss could occur if full compliance is not met.

How did the acquisitions in 2002 impact Abbott's financial statements?

In the second quarter of 2002, Abbott acquired the cardiovascular stent business of Biocompatibles International plc and certain technology rights from Medtronic, Inc., along with additional shares of Hokuriku Seiyaku Co., Ltd. These acquisitions had an aggregate cash purchase price of $586 million and resulted in a pretax charge for acquired in-process research and development of approximately $108 million.

What are the key patent expirations or challenges that investors should be aware of?

Key patent expirations and challenges include the U.S. compound patent for clarithromycin (Biaxin) expiring in 2005, although a significant portion of sales are covered by later-expiring patents. Patents for TriCor are being challenged by competitors. Synthroid's NDA was approved in 2002, but the FDA is studying conditions for competitors to rely on Abbott's NDA.

ABT 10-K FY2002 Annual Report — Revenue, Net Income, EPS

Summary

Abbott Laboratories' 2002 10-K filing highlights a year of significant revenue growth, driven primarily by strong performance in its Pharmaceutical and International segments. The company's diversified health care product portfolio, spanning pharmaceuticals, diagnostics, hospital products, and nutritional products, positions it well in a competitive landscape. A key development was the FDA approval of Humira™ for rheumatoid arthritis, expected to contribute significantly to future revenue. The company also made strategic acquisitions, including cardiovascular stent businesses, to bolster its product offerings. Despite a $129 million charge related to FDA consent decree compliance in its diagnostics division and ongoing litigation and investigations, Abbott maintained a strong financial position, supported by robust operating cash flow and an unused line of credit. The company continued its commitment to research and development, investing over $1.5 billion to drive innovation across its key segments. Overall, the filing indicates a company focused on growth through innovation and strategic investments, while navigating regulatory and legal challenges. Investors can take comfort in the diversified revenue streams and strong market positions of Abbott's product categories. However, the ongoing FDA consent decree in the diagnostics segment and various litigations warrant continued monitoring.

Key Highlights

1Abbott Laboratories reported significant revenue growth in 2002, with net sales reaching $17.7 billion, an increase of 8.6% over 2001.

2The Pharmaceutical Products segment showed robust growth of 13.5%, driven by key products like Depakote, Biaxin, and the new Humira™.

3Strategic acquisitions in the cardiovascular stent business and of Hokuriku Seiyaku Co., Ltd. aimed to expand the company's product portfolio.

4The company incurred a $129 million pretax charge in 2002 related to its diagnostics manufacturing operations' non-compliance with FDA Quality System Regulation, with further compliance efforts ongoing.

5Research and development expenses remained high, exceeding $1.5 billion, underscoring Abbott's commitment to innovation, particularly in pharmaceuticals and diagnostics.

6The company maintained a strong financial position, with total assets of $24.3 billion and significant operating cash flow, supported by $3 billion in unused lines of credit.

7Abbott is involved in several legal proceedings and investigations, including those related to pharmaceutical pricing and marketing practices, which the company believes will not materially affect its financial position, except for an ongoing investigation into its enteral nutritional business.

Frequently Asked Questions